Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Novartis AG | Ligelizumab (QGE031) - (Pearl 1) | Chronic spontaneous urticaria (CSU) | Phase 3 | Subcutaneous | Immunology | |
| Novartis AG | Canakinumab (ACZ885) - (CANOPY-1) | Non-small cell lung cancer (NSCLC) | Phase 3 | Trial Discontinued | Subcutaneous | Oncology |
| Novartis AG | BEOVU (Brolucizumab) - (KINGFISHER) | Diabetic macular edema (DME) | Phase 3 | Intravitreal injection | Opthalmic | |
| Novartis AG | Scemblix (asciminib) - (ASCEMBL) | Chronic myeloid leukemia (CML) | Phase 3 | Ongoing | Oral | Oncology |
| Novartis AG | COSENTYX (secukinumab) | Psoriatic arthritis | Phase 3 | Trial Discontinued | Subcutaneous | Immunology: Anti-TNF |
| Novartis AG | QAW039 (fevipiprant) - (ZEAL) | Asthma | Phase 3 | Trial Discontinued | oral | Respiratory |
| Novartis AG | PDR001 | Metastatic melanoma | Phase 3 | Intravenous | Oncology | |
| Novartis AG | Gantenerumab - (GRADUATE) | Early Alzheimer's disease | Phase 3 | Trial Completed | Intravenous | Neurology |
